期刊文献+

武汉地区人群血清游离脂肪酸参考区间的探索

Investigation on reference interval of serum non-esterified fatty acid among population in Wuhan area
下载PDF
导出
摘要 目的初步建立武汉地区人群血清游离脂肪酸(NEFA)酶法参考区间。方法选择该院健康体检者1 250例作为研究对象,采用奥林巴斯AU5400生化分析仪及Sekisui酶法检测试剂检测血清NEFA。回归分析NEFA的影响因素,正态分布法估计NEFA 95%参考区间,并验证参考区间。结果回归分析显示体质量指数(BMI)及年龄对NEFA有显著影响(P〈0.01)。NEFA在大于或等于60岁最高,18-〈45岁次之,45-〈60岁最低;NEFA在BMI〈18.5kg/m2组最高。估计武汉地区健康人群NEFA 95%参考区间为204.6-975.2μmol/L。临床验证者的测定范围为242.0-831.2μmol/L,符合上述参考区间。结论初步建立武汉地区健康人群NEFA参考区间。 Objective To preliminarily establish the reference interval of serum non-esterified fatty acids(NEFA)among population in Wuhan area by enzymatic assay.Methods NEFA level of serum samples from A total of 1 250 individuals undergoing healthy physical examination in our hospital were selected as the research subjects.The Olympus AU5400 biochemistry analyzer and SEKISUI reagents were adopted to detect serum NEFA level.The regression analysis was adopted to analyze the NEFA influencing factors.The NEFA 95% reference interval was estimated by using the normal distribution method and the reference interval was verified.Results The regression analysis showed that the body mass index(BMI)and age had significant effect on NEFA(P〈0.01).NEFA was highest in the group aged≥60years old,followed by the group of 18-45years old,and lowest in the group of45-60 years old;NEFA was highest in the group of BMI18.5kg/m2.The 95%reference interval of NEFA for healthy population in Wuhan area was estimated as 204.6-975.2μmol/L.The detected NEFA level for clinical verifiers was 242.0-831.2μmol/L,which conformed to the above reference interval.Conclusion The serum NEFA reference interval among healthy population in Wuhan area is primarily established.
出处 《国际检验医学杂志》 CAS 2016年第23期3249-3251,共3页 International Journal of Laboratory Medicine
基金 国家重点基础研究发展规划"973"资助项目(2012CB720605)
关键词 酶法 血清游离脂肪酸 参考区间 enzymatic assay serum non-esterified fatty acids reference interval
  • 相关文献

参考文献3

二级参考文献25

  • 1陈江,姜东林,曹利民.2型糖尿病患者血浆抵抗素和游离脂肪酸与胰岛素抵抗关系研究[J].中国微循环,2006,10(1):52-54. 被引量:8
  • 2Fuentes-Arderiu X, Mas-Serra R, Aluma-Trullas A, et al. Guideline for the production of multicentre physiological reference values using the same measurement system. A proposal of the Catalan Association for Clinical Laboratory Sciences. Clin Chem Lab Med ,2004,42:778-782.
  • 3NCCLS C28-A2 How to Define and Reference Intervals in the Clinical Laboratory. NCCLS,2000.
  • 4NCCLS EP9-A Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline-Second Edition. NCCLS, 1995.
  • 5NCCLS EP5 -A2 Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline-Second Edition. NCCLS, 1999.
  • 6中华人民共和国卫生部.医疗机构临床实验室管理办法及配套文件.2006:59-62.
  • 7Solberg HE, Stature D. International Federation of Clinical Chemistry IFCC. IFCC recommendation-theory of reference values. Part 4. Control of analytical variation in the production, transfer and application of reverence values. Clin Chim Acta, 1991,202:S5-11.
  • 8Boden .G, Chen X, Ruzi J, etal. mechanisms of fatty acids induced inhibi- tion of glucose uptake[J]. J Clin Endocrinol Metab, 2001,86: 2153.
  • 9NCCLS. EP5-A2: Evalution of precision performance of quantitative mea- surement methods; approved guideline-second edition [ S]. Wayne PA, 2004.
  • 10NCCLS. EP7-A2: Interference testing in clinical chemistry; approved guideline-second edition[ S ]. Wayne PA, 2005.

共引文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部